Skip to content
Neighborhood
Events & Culture
Transportation
Diversity
Future of Work
COVID-19
About
Join KSA
Menu
Neighborhood
Events & Culture
Transportation
Diversity
Future of Work
COVID-19
About
Join KSA
Announcements
Biogen, placing a major bet on a once-failed treatment, is paying $1.53 billion for the commercial rights to a Sage Therapeutics’ oral depression drug, zuranolone.
Dec 01, 2020
Share
Share on Twitter
Share on Facebook
Close
Previous
←
Next
→
/